(0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Feb 27, 2006 8:30 AM - Nov 22, 2022 12:00 AM

Basics of the IND Phase

Overview

DIA is pleased to present a four-part course in which you will learn about FDA regulations and expectations for the content, submission, and review of Investigational New Drug (IND) Products and the importance of regulatory strategy. This online course focuses on drug and well characterized biological products and not the regulatory process for devices, generic products, OTC products, or traditional biologics.

Featured topics

  • The Fundamentals of the Investigational New Drug Products
    • Preparation
    • Content
    • Strategy
  • Activities and Submissions Required to Maintain an IND
  • Special Regulatory Considerations for Clinical Development

Who should attend?

  • Regulatory affairs professionals new to the IND process
  • Clinical research and development professionals
  • Biostatisticians
  • Basic researchers
  • Quality and manufacturing professionals
  • Medical writers
  • Business professionals
  • Project Managers

Learning objectives

At the conclusion of this activity, participants should be able to:

  • Explain the importance of incorporating regulatory strategy into the drug development plan
  • Describe the FDA review processes for evaluating INDs
  • Plan and prepare an IND, and know the reporting requirements for IND amendments
  • Identify regulatory mechanisms to facilitate development of new therapies

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.